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Preeclampsia is a multiorgan, heterogeneous disorder of pregnancy associated with signiﬁcant maternal and neonatal morbidity
and mortality. Optimal strategies in the care of the women with preeclampsia have not been fully elucidated, leaving physicians
withincompletedatatoguidetheirclinicaldecisionmaking.Becausepreeclampsiaisaprogressivedisorder,insomecircumstances,
delivery is needed to halt the progression to the beneﬁt of the mother and fetus. However, the need for premature delivery
has adverse eﬀects on important neonatal outcomes not limited to the most premature infants. Late-preterm infants account
for approximately two thirds of all preterm deliveries and are at signiﬁcant risk for morbidity and mortality. Reviewed is the
current literatureinthediagnosisandobstetrical managementofpreeclampsia,theoutcomesoflate-preterm infants,andpotential
strategies to optimize fetal outcomes in pregnancies complicated by preeclampsia.
1.Introduction
Preeclampsia is a multisystem, highly variable disorder
unique to pregnancy and a leading cause of maternal
and fetal/neonatal morbidity and mortality [1–7]. While
preeclampsia complicates 6%–10% of all pregnancies in the
United States, the incidence is believed to be even higher in
underdeveloped countries [8, 9]. Recent evidence suggests
that preeclampsia accounts for approximately 15.9% of all
maternal deaths in the United States and is a major cause of
perinatalmorbidityanddeath[10,11].Therefore,physicians
must carefully weigh the risks to both mother and fetus
in management decisions. To that end, optimal treatment
strategies have not been fully deﬁned, leaving physicians
with incomplete data to guide their patient care practices [8,
12, 13]. The increased incidence of perinatal morbidity and
mortality seen in pregnancies complicated by preeclampsia,
although complex and multifactorial, is primarily due to the
need for premature delivery and uteroplacental insuﬃciency
resulting in a compromise of blood ﬂow to the fetus [14,
15]. This paper will review the diagnosis and obstetrical
management of preeclampsia, the outcomes of late-preterm
infants, and potentialstrategies tooptimizefetal outcomesin
pregnancies complicated by preeclampsia.
2.Diagnosis ofPreeclampsia
Antepartum diagnosis of mild, moderate, and severe
preeclampsia is based on series of deﬁned criteria occurring
after 20 weeks of gestation [16]. Severe PE is deﬁned
as a blood pressure greater than 160mmHg (systolic) or
110mmHg (diastolic) associated with proteinuria greater
thanorequalto5gramsperday.Furthermore,PEisregarded
as severe in the presence of multiorgan involvement includ-
ing thrombocytopenia (platelet count less than 100,000/uL),
pulmonary edema, or oliguria (less than 500mL per day).
In contrast, mild PE is characterized by an elevated blood
pressure less than 160mmHg (systolic) or 120mmHg
(diastolic) with proteinuria greater than 300mg, but less
than 5g, per day [9]. Ongoing debate on the optimal way
to classify disease severity in preeclampsia is likely due to
incomplete knowledge of the underlying pathophysiology of
disorder, with the clinical and laboratory manifestations of2 Journal of Pregnancy
preeclampsia representing a common endpoint for a variety
of maternal disease states during pregnancy [17].
3.CurrentObstetricalPractice
The only deﬁnitive cure for preeclampsia is delivery of the
fetus and placenta [18]. Given the progressive nature of the
disorder, delivery is often necessary to minimize maternal
morbidity and mortality. On the other hand, one of the
primary goals of obstetricians is to deliver infants who
are functionally mature and capable of adapting to the
extrauterineenvironment withouttheneedforintensivecare
[19]. Therefore, in pregnancies complicated by preeclamp-
sia, obstetricians must balance the need for achieving in
utero fetal maturation with the maternal and fetal risks of
continuing pregnancy, including progression to eclampsia,
abruptio placentae, and HELLP syndrome, as well as fetal
growth restriction and demise [17, 20–22]. At the present
time, delivery is typically recommended for women who
develop preeclampsia, regardless of disease severity, at 37
gestational weeks [23]. At this gestational age, the maternal
and fetal risks during expectant management clearly out-
weigh potential beneﬁts to the fetus. In addition, delivery
is recommended for all women with severe preeclampsia no
later than 34 weeks gestation [9, 24]. However, there are no
clear guidelines addressing the optimal timing for delivery
in women with mild preeclampsia between 34 and 36 weeks
gestation (late-preterm gestation) who remain in stable con-
dition [25]. Although is it believed that the majority of late-
pretermdeliveries in pregnancies with mild preeclampsia are
due to maternal or fetal conditions warranting intervention,
recent evidence suggests that iatrogenic elective late-preterm
delivery remains a part of obstetrical practice [26]. For
instance, a recent study of 1,850 women with stable mild
gestational hypertension showed that over one-quarter of
patients (25.5%), without any maternal or fetal indications,
had iatrogenic elective late-preterm deliveries [27].
4.ConsequencesofPrematureDelivery:
Late-PretermInfant Outcomes
Late-preterm births represent the fastest growing subset of
premature births. Data from 1992 to 2002 show that two
thirds of the decade’s increase in preterm births was due to
a rise in the incidence of late-preterm deliveries [28]. This
increase was largely attributed to obstetrical and pediatric
disciplines considering late-preterm infants functionally full
term [29]. However, accumulating evidence suggests that
late-preterm infants are, in fact, physiologically immature
compared with infants born at term and are at signiﬁcant
risk for a broad range of complications [30–34].
4.1. Survival. Neonatal and infant mortality rates are
consistently higher in late-preterm infants than in term
infants [35–37]. A population-based study from the British
Columbia Perinatal Database Registry investigated mortality
statistics for a cohort of late-preterm infants (33–36 weeks,
n = 6391) compared to term infants (37–40 weeks, n =
88, 867) from 1999–2002. The authors found that neonatal
mortality (deaths among infants 0–27 days’ chronological
age) and infant mortality (death among infants 0–364days’
chronological age) was 5.5 and 3.5 times greater in the
late-preterm group, respectively. Interestingly, the authors
also noted that even after excluding the neonatal period,
the risk of mortality between 28days and 1year was still 2
times higher in the late-preterm group [38]. This ﬁnding is
consistent with previous epidemiological data from Canada
and the United States showing an increase in the gestation-
speciﬁc neonatal mortality rate of late-preterm infants
between 6 and 8.5 times when compared with term infants
[39, 40]. A study by Young and colleagues determined the
relative risk for mortality rate for each weekly estimated
gestational age cohort from 34–42 weeks, using 40weeks as
the reference cohort. The authors showed that mortality and
the relative risk of death decreases with each increasing week
in gestational age. Speciﬁcally, the infant mortality rates in
pregnancies delivered at 34, 35, and 36 weeks gestation were
12.5, 8.7, and 6.3 times higher, respectively, compared to
term (40weeks) controls [41].
4.2. Morbidity. In the past, epidemiology and health service
research, as well as patient-care guidelines, suggested that
34weeks gestation was a surrogate for fetal maturity [42].
Infants born between 34 and 36 weeks gestation were labeled
as “near-term” infants and were believed to be at a low risk
for signiﬁcant morbidities [43, 44]. This led to a relative lack
of attention of the neonatal consequences when delivery was
beingconsideredbeyond34weeksgestation[45].However,a
growing body of literature indicates that late-preterm infants
are at greater risk for a number of complications, primarily
respiratory problems. Several studies have shown that late-
preterm infants are at increased risk for respiratory dis-
tress syndrome (RDS), transient tachypnea of the newborn
(TTN), persistent pulmonary hypertension (PPHN), and
respiratory failure compared to term infants [30, 46–49].
Evidence suggests that late-preterm infants have a nine
times greater incidence of respiratory distress syndrome
than term infants (28.9% versus 4.2%, P<. 001) [34].
Importantly, evidence suggests a signiﬁcant reduction in
neonatal respiratory morbidity when gestation is extended
beyond 34 weeks, a beneﬁt seen for each week increase
in gestational age up to term [50, 51]. In a population-
based study of neonatal morbidity in the United States, the
incidence of RDS was 7.4% at 34 weeks, 4.5% at 35 weeks,
2.3% at 36 weeks, and 1.2% at 37 weeks [50]. A more recent
study noted infants born at 34 weeks were 18 times more
likely to require supplemental oxygen for at least one hour
and over 19 times more likely to require assisted ventilation
comparedtoinfants bornat38–40weeksgestation[52].This
suggests that there is a signiﬁcant portion of late-preterm




5.1. Risk of Fetal Demise/Stillbirth. Stillbirth represents an
important cause of fetal loss in the late-preterm infant [53].Journal of Pregnancy 3
Although greater than 90% of fetal deaths occur in the ﬁrst
20 weeks of gestation, the rate of stillbirth is approximately 3
per 1000 live births beyond 28 weeks gestation. Interestingly,
evidence suggests that beginning at approximately 36 weeks,
the risk of intrauterine fetal demise increases substantially
[54]. Severe preeclampsia represents signiﬁcant risk factor
for intrauterine fetal demise, with estimated stillbirth rate of
21per1000[55].Inthesettingofseverepreeclampsia,aspre-
viouslydiscussed, therisk offetaldeathoutweighsthepoten-
tial beneﬁts of pregnancy prolongation. However, in cases of
mild preeclampsia, the risk of fetal demise is over 50% less
than pregnancies with severe preeclampsia (stillbirth rate of
9 per 1000) [55]. Despite a paucity of data to guide clinical
decision making in pregnancies with mild preeclampsia,
obstetriciansare lefttobalance thesmall, butimportant risks
of fetal demise, with the beneﬁts of pregnancy prolongation
and potential for continued in utero maturation, particularly
in pregnancies less than 37 weeks gestation.
5.2. Intrauterine Growth Restriction (IUGR). Fetal growth is
a useful marker for fetal well-being [56, 57]. Pregnancies
complicated by intrauterine growth restriction (IUGR),
deﬁned as a pathological process of reduced fetal growth,
have been associated with an increase in perinatal mor-
tality [58, 59]. Preeclampsia, a condition characterized
by decreased uteroplacental blood ﬂow and ischemia, is
a signiﬁcant risk factor in the development of IUGR
and represents the most common cause of IUGR in the
nonanomalous infant. Data has consistently shown that for
any given gestational age at birth, including term, a weight
below the 10th percentile signiﬁcantly increases the risk
of mortality [60]. To that end, an infant at 38–40 weeks
with a weight of 1,250grams has a signiﬁcantly greater
mortality risk than one born of similar weight at 32weeks
[61]. It is important to note that while reduced birth size is
associated with severe preeclampsia, it has not been as well
described in pregnancies complicated by mild preeclampsia
[62]. Ødeg˚ ard et al. showed pregnancies complicated by
severe preelampsia had infant birth weights 12% lower than
expected, while pregnancies with mild preeclampsia showed
no diﬀerence in weight gain from expected norms [63].
Previous guidelines have suggested that the late-preterm
IUGR fetus should be delivered if there is any evidence
of maternal hypertension [61]. However, the high risk of
complication related to preterm delivery in the late-preterm
infant, as well as the apparent negligible eﬀect of mild
preeclampsia on fetal growth and maternal health, highlight
the importance of carefully selecting the appropriate time of
delivery in pregnancies complicated by IUGR [64].
5.3. HematologicEﬀects. Maternal preeclampsia can result in
neonatal thrombocytopenia, typically deﬁned as a platelet
count less than 150,000/uL [65]. In pregnancies complicated
by preeclampsia, thrombocytopenia is generally identiﬁed
at birth or within the ﬁrst 2–3 days following delivery,
with resolution by 10 days of life in most cases [66].
Severity of thrombocytopenia related to preeclampsia is
highly variable, with a small percentage of infants devel-
oping severe or clinically signiﬁcant thrombocytopenia
(<50,000/uL) [67, 68].The pathogenesis of thrombocytope-
nia among infants born to mothers with preeclampsia is
unknown[69].Onepotentialmechanisms isthatpreeclamp-
sia, and the resultant fetal hypoxia, has a direct depressant
eﬀectonmegakaryocyte proliferation[70].This issupported
by studies showing that growth-restricted neonates have
signiﬁcant megakaryocytopoeitic defects without evidence
of increased platelet destruction [71]. At present, there
is a paucity of evidence-based recommendations to guide
clinicians on which platelet counts warrant intervention
[72]. Given the inherent risks of platelet transfusions,
includingthe induction ofa systemic inﬂammatory response
and worsening of lung function immediately following the
transfusion, additional studies are needed to guide clinical
management [73, 74].
In addition to the well-described eﬀects of preeclampsia
on platelets, neonates delivered to women with preeclampsia
have a 50% incidence of neutropenia (deﬁned as absolute
neutrophil count less than 500) [75]. Neutropenia has a
variable course, typically lasting days to weeks in aﬀected
infants. The biologicalmechanism forpreeclampsiaresulting
in neonatal neutropenia has not been fully elucidated. One
potential mechanism is that preeclampsia, and the resultant
uteroplacental insuﬃciency, inhibits fetal bone marrow
production of the myeloid lineage manifested by a decrease
in neutrophil production [66]. Neutropenia associated with
maternal preeclampsia is also associated with reduced
numbers of circulating colony forming unit-granulocyte
macrophage (CFU-GM) and decreased neutrophil storage
pools [76]. Neutropenia is generally self-limited although
in some cases it may be severe enough to warrant therapy
with granulocyte-colony stimulating factor (G-CSF) [77].
Although some studies suggest that there is an increased
risk for nosocomial infection among aﬀected neonates
even after resolution of their neutropenia, other studies
have demonstrated no increased propensity for infection
[75, 78].
5.4. Bronchopulmonary Dysplasia (BPD). Although the
pathophysiology of preeclampsia is poorly deﬁned, evidence
suggests that abnormal placentation, characterized by shal-
low invasion of the maternal arteries, compromises uterine
blood ﬂow at the expense of the growing placenta and fetus
[79]. The resulting hypoxia and ischemia may restrict fetal
angiogenesis [80]. Considering the growing evidence sug-
gesting that preservation of in utero vascular growth is criti-
calinmaintenanceofalveolarization(“vascularhypothesisof
BPD”),itispossiblethatpreeclampsiamayaltercriticallung-
vessel interactions necessary for normal lung development
[81, 82]. A recent study shows that maternal preeclampsia
is, in fact, associated with an increased risk for development
of BPD, evenafter adjusting for gestational age, birth weight,
and other clinical confounders (OR 2.96, 95% CI 1.17-7.51,
P = .01) [83]. Additional studies have shown that BPD
occurs in infants of mothers with preeclampsia, but only
in the setting where preeclampsia is severe enough to lead
to fetal growth restriction [82]. Ongoing research is needed
to better understand the biological mechanisms linking in
utero disruption of angiogenesis, including preeclampsia,4 Journal of Pregnancy
and resultant impairments in fetal growth on important
neonatal outcomes [84].
5.5. Neurodevelopmental Outcome. Given that preeclampsia
is a heterogeneous disorder, it is not surprising that the
neurodevelopmental outcomes of exposed infants are highly
variable [85, 86]. Some evidence suggests that preeclampsia
is associated with a decreased risk of cerebral palsy. These
authors found a protective eﬀect of maternal preeclampsia
oncerebralpalsyregardlessofexposuretomagnesiumsulfate
[87]. In addition, there is some evidence to suggest a lower
incidence of IVH among infants born 26–30 weeks exposed
to maternal preeclampsia compared to age-matched controls
(4.8% versus 20.5%, P<. 001) [86]. However, some data
suggest infants born to mothers with preeclampsia have
lower MDI scores (Bayley II scales of infant development)
at 24 months of age compared to infants without maternal
preeclampsia (P = 0.04) [88]. The association between
maternal preeclampsia and worse neurodevelopmental out-
comes has been challenged by more recent evidence suggest-
ing that infants exposed to preeclampsia have, in fact, higher
scores on developmental testing at 18 months corrected
age [89]. Again, these diﬀerences highlight the fact that
preeclampsia represents a common endpoint for a number
of adverse maternal conditions and that eﬀorts to better
characterize subtypesof preeclampsia may allow for a clearer
understanding of the impact of preeclampsia on short and
long-term neonatal outcomes.
5.6. Fetal Origins of Adult Disease States. In utero develop-
mentischaracterizedbyrapidcellularandmoleculargrowth.
The ontological processes critical for maturation of the fetus
are highly sensitive to alterations in the intrauterine envi-
ronment [90]. Ongoing evidence suggests that various adult
disease states (hypertension, obesity, diabetes) may begin
during fetal development, and the insults from preeclampsia
exposure accrued during sensitive periods of development
may predispose an individual to an increased risk of disease
in adulthood [91]. Forexample, a population-based study of
over one million children exposed to preeclampsia showed
an increased risk of endocrine, nutritional, and metabolic
derangements during adolescence and early-adulthood (up
to 27 years of followup) among the exposed cohort. These
risk factors remain even after adjusting for diﬀerences in
lifestyle (smoking, exercise, socioeconomic status, and diet)
[92]. Epidemiological studies show that infants exposed
to preeclampsia during gestation are associated with an
increased risk of diabetes and cardiovascular morbidity in
adulthood [93]. These studies underscore the concept that
the physiologically immature fetus is highly susceptible to
disruptions in utero placental blood ﬂow and that insults
from preeclampsia exposure accrued during critical periods
of fetal development may predispose an individual to an
increased risk of disease beyond the immediate postnatal
period. Additional studies are needed to understand the
causal pathways that may drive disordered fetal develop-
ment in preeclampsia, as well as the potential impact of
preeclampsia in altering expression of key genes involved in
fetal programming and adult disease processes [94].
6.Medical Management:Optimizing
Fetal Outcomes
There are a limited number of therapeutic options in the
management of preeclampsia with known beneﬁt to the
fetus. Antepartum management routinely involves admin-
istration of antenatal steroids in anticipation of preterm
delivery. Antenatal administration of corticosteroids for as
few as 12–24 hours before delivery has been shown to
decrease morbidity and improve survival rates of infants
born before 34 weeks’ gestation [95]. However, considering
that the safety and eﬃcacy of antenatal corticosteroids
in the late-preterm infant remains unproven, additional
studies are warranted [96]. Magnesium sulfate, a commonly
used medication for seizure prophylaxis in women with
preeclampsia, has been shown to have a neuroprotective
eﬀect on the preterm infant. A recent meta-analysis of over
6000 infants showed that antenatal magnesium sulfate given
towomenatrisk forpretermbirthdecreased theincidenceof
cerebral palsy (RR 0.68, 95% CI 0.54–0.87) and gross motor
dysfunction (RR 0.61, 95% CI 0.44–0.85) [97]. Prospective,
randomized controlled trials have shown that magnesium
therapy is associated with a decreased incidence of cerebral
palsy among survivors exposed to the medication between
24 and 31 weeks gestation [98].
7.Conclusion
Historically, there has been a relative lack of consideration to
the complications of premature delivery at greater than 34
weeks gestation, with the belief that 34 weeks is a surrogate
marker for fetal maturity. Recent evidence suggests that
infants born between 34 and 36 weeks gestation are, in
fact, physiologically immature compared to term infants.
Furthermore, given the potential for preeclampsia to disrupt
mechanisms regulating fetal growth and development,a bet-
terunderstandingofthepathophysiologyofthedisordermay
allow us to develop strategies to prevent morbidities from
fetal through adult life. Because of the high variability of
each case, a general recommendation for the optimal timing
of delivery is not possible. However, based on the review
of data, we believe that a multidisciplinary, collaborative
approach between the ﬁelds of maternal-fetal medicine and
neonatologyisnecessary toweighthematernalandfetalrisks
of prolonging the pregnancy versus the potential beneﬁts of
further fetal maturation across most gestational ages.
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